Books and Book Chapters

    Leaf Curing Practices Alter Gene Expression and the Chemical Constituents of Tobacco Leaves

    Bovet, L.; Hilfiker, A.; Battey, J. N. D.; Sierro, N.; Goepfert, S.

    Date published
    Mar 17, 2020
    DOI
    10.1007/978-3-030-29493-9_6
    ISBN
    978-3-030-29493-9
    Published in
    The Tobacco Plant Genome
    Editors
    Ivanov, N. V.; Sierro, N.; Peitsch, M. C.
    Link to publication
    Topic
    Summary

    Tobacco leaves senesce during the early curing phase, and their constituents are altered via specific enzymatic activities. Levels of the reducing sugars glucose and fructose and those of total free amino acids increase via active protease activity and active synthesis processes. We used transcriptomics to identify the genes up- and downregulated in tobacco leaves from the Burley, Virginia, and Oriental varieties after 48 h of curing. Approximately 8% of the transcripts were upregulated, including 591 genes common to all three varieties, and especially genes associated with oxidation-reduction processes, transcription factors, proteolysis, and hydrolase activity. All of these have been linked to the cellular senescence process. Approximately 12% of the transcripts were downregulated, including 1,486 genes common to all three tobacco types; the genes with the highest fold changes were associated with general metabolic processes. Gene ontology overrepresentation analysis suggested that the three main axes governing the curing of tobacco are dehydration stress, amino acid alteration, and sucrose metabolism. We identified sucrose synthase (SUS) as a likely driver of the accumulation of reducing sugars during the water-deprivation response, and aspartate aminotransferase (AAT) as a catalyst of amino acid metabolism.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.